Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.39 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.39 |
| ▸ | ITGAV | P06756 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.39 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11037027 | 0.82 | ALDH1A1 (0.42) | ALDH1A1HPGDCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL12531104 | 0.82 | KDM4E (0.41) | KDM4EALDH1A1KMT2AHSD17B10MAPT | |
| SCHEMBL815103 | 0.79 | LMNA (0.58) | KDM4EALDH1A1KMT2AHSD17B10MAPT | |
| SCHEMBL80480 | 0.79 | LMNA (0.58) | KDM4EALDH1A1KMT2AHSD17B10MAPT | |
| SCHEMBL905284 | 0.79 | LMNA (0.58) | KDM4EALDH1A1KMT2AHSD17B10MAPT | |
| SCHEMBL16876472 | 0.78 | MEN1 (0.41) | KDM4EALDH1A1KMT2AHSD17B10MAPT | |
| SCHEMBL9786423 | 0.78 | ALDH1A1 (0.41) | KDM4EALDH1A1KMT2AHSD17B10MAPT | |
| SCHEMBL9786424 | 0.78 | ALDH1A1 (0.41) | KDM4EALDH1A1KMT2AHSD17B10MAPT | |
| SCHEMBL9786445 | 0.78 | ALDH1A1 (0.41) | KDM4EALDH1A1KMT2AHSD17B10MAPT | |
| SCHEMBL16876469 | 0.78 | MEN1 (0.41) | KDM4EALDH1A1KMT2AHSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116444506-A | Therapeutic compounds and compositions | 艾克赛特赫拉制药有限责任公司 | 2023-07-18 | — | — | CN | disclosed |
| US-6841682-B2 | Heterocycles useful in the treatment of benign prostatic hyperplasia | JANSEEN PHARMACEUTICA N.V. (BE) | 2005-01-11 | — | — | US | disclosed |
| EP-1273572-B1 | Thiophene substituted piperazines useful in the treatment of benign prostatic hyperplasia | ORTHO MCNEIL PHARM INC (US) | 2004-12-15 | — | — | EP | disclosed |
| EP-1273572-A1 | Thiophene substituted piperazines useful in the treatment of benign prostatic hyperplasia | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-01-08 | — | — | EP | disclosed |
| US-20020165219-A1 | Novel heterocycles useful in the treatment of benign prostatic hyperplasia | HUTCHINGS RICHARD H (US) | 2002-11-07 | — | — | US | disclosed |
| US-6384035-B1 | TREATING A DISEASE MEDIATED BY THE .ALPHA.-1.SUB.A ADRENERGIC RECEPTOR COMPRISING ADMINISTERING A COMPOUND | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-05-07 | — | — | US | disclosed |
| EP-1025085-A1 | HETEROCYCLES USEFUL IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA AND INTERMEDIATES THEREOF | Ortho-McNeil Pharmaceutical, Inc. (US) | 2000-08-09 | — | — | EP | disclosed |
| WO-1999019299-A1 | HETEROCYCLES USEFUL IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA AND INTERMEDIATES THEREOF | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 1999-04-22 | — | — | WO | disclosed |
| US-4435322-A | Heterocyclic compounds containing an alkoxycarbonyl and a substituted methyl group | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 1984-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165219-A1 | Novel heterocycles useful in the treatment of benign prostatic hyperplasia | ADRA1A, ADRB1, ADRA1D | KDM4E 2968/4885ALDH1A1 39/4885KMT2A 2395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.